参考文献
［1］NCCN Clinical Practice Guidelines in Oncology（NCCN Guidelines）Cervical Cancer version 1.2016.
［2］Vijayalakshmi R，Viveka T S，Malliga J S，et al.Use of fast transfer analysis cartridges for Cervical sampling and real time PCR based high risk HPV testing in cervical cancer prevention—a feasibility study from south India［J］.Asian Pac J Cancer Prev，2015，16（14）：5993－5999.
［3］Zhang Q W，Xie W Y，et al.Epidemiological investigation and risk factors for cervical cancer screening among women in rural areas of henan province China［J］.MED SCI MONIT，2016，22：1858－1865
［4］Makwe C C，Anorrlu R I，Ka O.Human papillomavirus（HPV）infection and vaccines：knowledge，attitude and perception among female students at the University of Lagos，Lagos，Nigeria［J］.J Epidemiol，2012，2（4）：199－206.
［5］Berenice I A，Enoc－Mariano C M，Veronica A V，et al.Cervical carcinoma in Southern Mexico：Human papillomavirus and cofactors［J］.Cancer Detection and Prevention，2009，32（4）：300－307.
［6］Castanon A，Landy R，Brocklehurst P，et al.PaCT study Group.Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England：nested case－control study［J］.BMJ，2014，349：g6223.
［7］Dillner J，Rebolj M，Birembaut P，et al.Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening：joint European cohort study［J］.BMJ，2008，237：a1754.
［8］Zhang X，Zhang L，Tian C，et al.Genetic variants and risk of cervical cancer：epidemiological evidence，meta－analysis and research review［J］.BJOG，2014，DOI：10.1111／1471－0528.12638.
［9］樊晓妹，单保恩，李魁秀.基因多态性与子宫颈癌易感性研究进展［J］.中华肿瘤防治杂志，2014，21（14）：1125－1128.
［10］石玉荣，耿建，程龙强，等.细胞色素P450 1A1基因多态性与子宫颈癌的相关性［J］.复旦大学学报（医学版），2011，38（5）：428－431.(https://www.daowen.com)
［11］曹振东，白慧杰，王胜林，等.64排螺旋CT对子宫颈癌转移淋巴结的诊断价值［J］.河北医药，2009，31（15）：1892－1894.
［12］Manfredi R，Gui B，Giovanzana A，et al.Localized cervical cancer（stage＜ⅡB）：accuracy of MR imaging in planning less extensive surgery［J］.Radiol Med，2009，114（6）：960－975.
［13］张孝春.CT和MRI在子宫颈癌分期诊断中的应用效果对比分析［J］.2012，18（25）：148－149.
［14］Kitahima K，Murakami K，Kaji Y，et al.Established，emerging and future applications of FDG－PET－CT in the uterine cancer［R］.Clinical Radiology，2011，66（4）：297－307.
［15］Harry V N.Novel imaging techniques as response biomarkers in cervical cancer［J］.Gynecologic Oncology，2010，116（2）：253－261.
［16］Ferrandina G，Macchia C，Legge E，et al.Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy association with pathological response to treatment and clinical outcome［J］.Oncology，2008，741－742.
［17］Schiller J T，Castel lsague X，Villa L L，et al.An update of prophylactic human papillomavirus L1virus－like particle vaccine clinical trial results［J］.Vaccine，2008，26（10）：53－61.
［18］Joura E A，Giuliano A R，Iversen O E，et al.A 9－valent HPV vaccine against infection and intraepithelial neoplasia in women［J］.N Engl J Med，2015，372（8）：711－723.
［19］Arbyn M，Rebolj M，De Kok I M，et al.The challenges of organizing cervical screening programmes in the 15old member states of the European Union［J］.EUR J Cancer，2009，45（15）：2671－2678.